Therapeutic Effects of hiPSC-Derived Glial and Neuronal Progenitor Cells-Conditioned Medium in Experimental Ischemic Stroke in Rats.
Animals
Cells, Cultured
Culture Media, Conditioned
/ metabolism
Disease Models, Animal
Humans
Induced Pluripotent Stem Cells
/ cytology
Infarction, Middle Cerebral Artery
/ metabolism
Infusions, Intra-Arterial
Ischemic Stroke
/ metabolism
Male
Neural Stem Cells
/ cytology
Neuroglia
/ cytology
Rats
Rats, Wistar
MCAO
conditioned medium
glial progenitor cells
induced pluripotent stem cells (iPSCs)
ischemic stroke
neuronal progenitor cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
09
03
2021
revised:
12
04
2021
accepted:
26
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Transplantation of various types of stem cells as a possible therapy for stroke has been tested for years, and the results are promising. Recent investigations have shown that the administration of the conditioned media obtained after stem cell cultivation can also be effective in the therapy of the central nervous system pathology (hypothesis of their paracrine action). The aim of this study was to evaluate the therapeutic effects of the conditioned medium of hiPSC-derived glial and neuronal progenitor cells in the rat middle cerebral artery occlusion model of the ischemic stroke. Secretory activity of the cultured neuronal and glial progenitor cells was evaluated by proteomic and immunosorbent-based approaches. Therapeutic effects were assessed by overall survival, neurologic deficit and infarct volume dynamics, as well as by the end-point values of the apoptosis- and inflammation-related gene expression levels, the extent of microglia/macrophage infiltration and the numbers of formed blood vessels in the affected area of the brain. As a result, 31% of the protein species discovered in glial progenitor cells-conditioned medium and 45% in neuronal progenitor cells-conditioned medium were cell type specific. The glial progenitor cell-conditioned media showed a higher content of neurotrophins (BDNF, GDNF, CNTF and NGF). We showed that intra-arterial administration of glial progenitor cells-conditioned medium promoted a faster decrease in neurological deficit compared to the control group, reduced microglia/macrophage infiltration, reduced expression of pro-apoptotic gene
Identifiants
pubmed: 33946667
pii: ijms22094694
doi: 10.3390/ijms22094694
pmc: PMC8125106
pii:
doi:
Substances chimiques
Culture Media, Conditioned
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Higher Education of the Russian Federation
Références
Nat Med. 2015 Feb;21(2):140-9
pubmed: 25581518
Nat Med. 2005 May;11(5):499-506
pubmed: 15834428
Brain Res. 2013 Mar 15;1500:88-98
pubmed: 23348379
Exp Ther Med. 2018 Jun;15(6):4777-4784
pubmed: 29805495
Cytotherapy. 2014 May;16(5):579-85
pubmed: 24113425
Nature. 2017 Apr 27;544(7651):488-492
pubmed: 28424512
Regen Med. 2010 Jan;5(1):121-43
pubmed: 20017699
Nat Biotechnol. 2009 Mar;27(3):275-80
pubmed: 19252484
J Neurosci. 2000 Dec 1;20(23):8597-603
pubmed: 11102463
PLoS One. 2017 Feb 16;12(2):e0171558
pubmed: 28207745
Brain Res. 2006 Oct 20;1116(1):12-8
pubmed: 16956589
Front Cell Dev Biol. 2015 Feb 02;3:2
pubmed: 25699255
Cell Mol Life Sci. 2011 Dec;68(24):3995-4008
pubmed: 21786144
Mol Cell Proteomics. 2005 Aug;4(8):1085-94
pubmed: 15905179
J Biomed Sci. 2014 Jan 22;21:5
pubmed: 24447306
Cell Transplant. 2013;22(9):1541-52
pubmed: 23067568
Stroke. 2018 May;49(5):1075-1082
pubmed: 29669876
Expert Rev Proteomics. 2010 Apr;7(2):263-74
pubmed: 20377392
Neurol Sci. 2020 Jun;41(6):1451-1458
pubmed: 32086687
Front Neurosci. 2021 Mar 02;15:641970
pubmed: 33737862
Stroke. 1989 Jan;20(1):84-91
pubmed: 2643202
Proteomics. 2014 Mar;14(4-5):378-98
pubmed: 24124134
J Cereb Blood Flow Metab. 2018 Aug;38(8):1276-1292
pubmed: 29768965
FEBS Lett. 2005 May 23;579(13):2788-94
pubmed: 15907482
EMBO J. 2016 Feb 1;35(3):239-57
pubmed: 26758544
J Chem Neuroanat. 2019 Apr;97:87-98
pubmed: 30790626
Expert Rev Proteomics. 2020 Mar;17(3):207-220
pubmed: 32187501
Appl Physiol Nutr Metab. 2017 Aug;42(8):855-860
pubmed: 28388366
Cell Stress Chaperones. 2014 Jan;19(1):115-34
pubmed: 23761196
Biomaterials. 2016 Jul;94:45-56
pubmed: 27101205
Methods Mol Biol. 2016;1416:123-46
pubmed: 27236669
Exp Transl Stroke Med. 2010 Jul 19;2(1):13
pubmed: 20642841
Stroke. 2011 Mar;42(3):764-9
pubmed: 21273567
Stem Cells Int. 2018 Apr 3;2018:4659159
pubmed: 29765412
PLoS One. 2018 Nov 21;13(11):e0205563
pubmed: 30462647
Stem Cell Reports. 2017 Aug 8;9(2):600-614
pubmed: 28757165
Stem Cells Dev. 2020 Aug;29(16):1084-1095
pubmed: 32560594
PLoS One. 2015 Jun 15;10(6):e0127302
pubmed: 26075717
Prog Neurobiol. 2018 Mar;162:37-69
pubmed: 29247683
Lipids. 2002 Sep;37(9):925-8
pubmed: 12458630
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45
pubmed: 18952487
Front Neurol. 2019 Aug 28;10:908
pubmed: 31555195
Maxillofac Plast Reconstr Surg. 2017 Mar 25;39(1):8
pubmed: 28405581
J Neurosci Res. 2009 Apr;87(5):1098-106
pubmed: 19021297
Proteomics. 2011 Mar;11(5):996-9
pubmed: 21337703
Biomed Res Int. 2014;2014:965849
pubmed: 25530971
Brain Behav. 2019 Mar;9(3):e01214
pubmed: 30747485
Cytokine Growth Factor Rev. 2019 Apr;46:1-9
pubmed: 30954374
Proteomics. 2014 Jul;14(13-14):1604-9
pubmed: 24753479
Stem Cells Transl Med. 2018 Nov;7(11):829-838
pubmed: 30238668
Transl Stroke Res. 2018 Aug;9(4):417-425
pubmed: 29178027
Neuron Glia Biol. 2004 Aug;1(3):193-9
pubmed: 16845437
Steroids. 2007 May;72(5):381-405
pubmed: 17379265